MedTrace Logo

Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment

NCT03228498 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2020-01-13

No results posted yet for this study

Summary

The purpose of this study is to assess whether the combination of choline alphoscerate 1200mg per day and nimodipine 90mg per day given orally is more effective than the combination nimodipine placebo in reducing cognitive decline in patients with subcortical vascular cognitive impairment

Conditions

  • Vascular Cognitive Impairment

Interventions

DRUG

Choline alphoscerate

Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d

DRUG

Placebo

Placebo b.i.d plus Nimodipine 30 mg t.i.d

Sponsors & Collaborators

  • MDM S.p.A.

    collaborator OTHER

  • Azienda Ospedaliero-Universitaria Careggi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-02
Primary Completion
2019-07-09
Completion
2019-07-09

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03228498 on ClinicalTrials.gov